公开(公告)号：US20220331309A1

公开(公告)日：2022-10-20

申请号：US17636133

申请日：2020-08-19

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Ishani Savant Landry ,  Kenya Nakai ,  Yukiko Miyajima ,  Yosuke Nakatani ,  Takashi Ueno ,  Edgar Schuck

IPC: A61K31/496 ,  A61K31/4709 ,  A61K31/70 ,  A61P43/00 ,  A61K31/135 ,  A61K38/00

Abstract: The present invention provides an oral pharmaceutical composition for treating insomnia, comprising lemborexant or a pharmaceutically acceptable salt thereof, wherein a normal dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 to 10 mg per day, provided that a dose of the lemborexant or pharmaceutically acceptable salt thereof is 2.5 mg per day when the pharmaceutical composition is administered to a patient together with the agent capable of moderately or strongly inhibiting CYP3A, and/or a dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 mg per day when the pharmaceutical composition is administered to the patient together with the agent capable of weakly inhibiting CYP3A.